Christopher Cao1, Daniel Wang2, Caroline Chung2, David Tian3, Andreas Rimner4, James Huang5, David R Jones6. 1. Thoracic Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY; Collaborative Research Group, Macquarie University, Sydney, Australia. 2. Department of Medicine, Cornell University, New York, NY. 3. Collaborative Research Group, Macquarie University, Sydney, Australia. 4. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Thoracic Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY. 6. Thoracic Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: jonesd2@mskcc.org.
Abstract
OBJECTIVE: Stereotactic body radiation therapy is the preferred treatment modality for patients with inoperable early-stage non-small cell lung cancer. However, comparative outcomes between stereotactic body radiation therapy and surgery for high-risk patients remain controversial. The primary aim of the present meta-analysis was to assess overall survival in matched and unmatched patient cohorts undergoing stereotactic body radiation therapy or surgery. Secondary end points included cancer-specific survival, disease-free survival, disease recurrence, and perioperative outcomes. METHODS: A systematic review of relevant studies was performed through online databases using predefined criteria. The most updated studies were selected for meta-analysis according to unmatched and matched patient cohorts. RESULTS: Thirty-two studies were identified in the systematic review, and 23 were selected for quantitative analysis. Surgery was associated with superior overall survival in both unmatched (odds ratio, 2.49; 95% confidence interval, 2.10-2.94; P < .00001) and matched (odds ratio, 1.71; 95% confidence interval, 1.52-1.93; P < .00001) cohorts. Subgroup analysis demonstrated superior overall survival for lobectomy and sublobar resection compared with stereotactic body radiation therapy. In unmatched and matched cohorts, cancer-specific survival, disease-free survival, and freedom from locoregional recurrence were superior after surgery. However, stereotactic body radiation therapy was associated with fewer perioperative deaths. CONCLUSIONS: The current evidence suggests surgery is superior to stereotactic body radiation therapy in terms of mid- and long-term clinical outcomes; stereotactic body radiation therapy is associated with lower perioperative mortality. However, the improved outcomes after surgery may be due at least in part to an imbalance of baseline characteristics. Future studies should aim to provide histopathologic confirmation of malignancy and compare stereotactic body radiation therapy with minimally invasive anatomical resections.
OBJECTIVE: Stereotactic body radiation therapy is the preferred treatment modality for patients with inoperable early-stage non-small cell lung cancer. However, comparative outcomes between stereotactic body radiation therapy and surgery for high-risk patients remain controversial. The primary aim of the present meta-analysis was to assess overall survival in matched and unmatched patient cohorts undergoing stereotactic body radiation therapy or surgery. Secondary end points included cancer-specific survival, disease-free survival, disease recurrence, and perioperative outcomes. METHODS: A systematic review of relevant studies was performed through online databases using predefined criteria. The most updated studies were selected for meta-analysis according to unmatched and matched patient cohorts. RESULTS: Thirty-two studies were identified in the systematic review, and 23 were selected for quantitative analysis. Surgery was associated with superior overall survival in both unmatched (odds ratio, 2.49; 95% confidence interval, 2.10-2.94; P < .00001) and matched (odds ratio, 1.71; 95% confidence interval, 1.52-1.93; P < .00001) cohorts. Subgroup analysis demonstrated superior overall survival for lobectomy and sublobar resection compared with stereotactic body radiation therapy. In unmatched and matched cohorts, cancer-specific survival, disease-free survival, and freedom from locoregional recurrence were superior after surgery. However, stereotactic body radiation therapy was associated with fewer perioperative deaths. CONCLUSIONS: The current evidence suggests surgery is superior to stereotactic body radiation therapy in terms of mid- and long-term clinical outcomes; stereotactic body radiation therapy is associated with lower perioperative mortality. However, the improved outcomes after surgery may be due at least in part to an imbalance of baseline characteristics. Future studies should aim to provide histopathologic confirmation of malignancy and compare stereotactic body radiation therapy with minimally invasive anatomical resections.
Authors: Neil M Woody; Kevin L Stephans; Gaurav Marwaha; Toufik Djemil; Gregory M M Videtic Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-01 Impact factor: 7.038
Authors: Matthew J Boyer; Christina D Williams; David H Harpole; Mark W Onaitis; Michael J Kelley; Joseph K Salama Journal: J Thorac Oncol Date: 2017-09-23 Impact factor: 15.609
Authors: Shervin M Shirvani; Jing Jiang; Joe Y Chang; James W Welsh; Daniel R Gomez; Stephen Swisher; Thomas A Buchholz; Benjamin D Smith Journal: Int J Radiat Oncol Biol Phys Date: 2012-09-11 Impact factor: 7.038
Authors: Gregory M M Videtic; Jessica Donington; Meredith Giuliani; John Heinzerling; Tomer Z Karas; Chris R Kelsey; Brian E Lally; Karen Latzka; Simon S Lo; Drew Moghanaki; Benjamin Movsas; Andreas Rimner; Michael Roach; George Rodrigues; Shervin M Shirvani; Charles B Simone; Robert Timmerman; Megan E Daly Journal: Pract Radiat Oncol Date: 2017-06-05
Authors: Shervin M Shirvani; Jing Jiang; Joe Y Chang; James Welsh; Anna Likhacheva; Thomas A Buchholz; Stephen G Swisher; Benjamin D Smith Journal: JAMA Surg Date: 2014-12 Impact factor: 14.766
Authors: N E Verstegen; J W A Oosterhuis; D A Palma; G Rodrigues; F J Lagerwaard; A van der Elst; R Mollema; W F van Tets; A Warner; J J A Joosten; M I Amir; C J A Haasbeek; E F Smit; B J Slotman; S Senan Journal: Ann Oncol Date: 2013-02-20 Impact factor: 32.976
Authors: Daniel J Boffa; Mark S Allen; Joshua D Grab; Henning A Gaissert; David H Harpole; Cameron D Wright Journal: J Thorac Cardiovasc Surg Date: 2007-12-21 Impact factor: 5.209
Authors: Shannon M Nugent; Sara E Golden; Donald R Sullivan; Charles R Thomas; Juan Wisnivesky; Somnath Saha; Christopher G Slatore Journal: Med Oncol Date: 2022-09-29 Impact factor: 3.738
Authors: Julie K Jang; Scott M Atay; Li Ding; Elizabeth A David; Sean C Wightman; Anthony W Kim; Jason C Ye Journal: Am J Clin Oncol Date: 2022-04-01 Impact factor: 2.339
Authors: Naomi K Atkins; Jasraj Marjara; Jussuf T Kaifi; Jeffrey R Kunin; Sachin S Saboo; Ryan M Davis; Ambarish P Bhat Journal: J Clin Imaging Sci Date: 2020-06-06